Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M708289200 on March 24, 2008

J. Biol. Chem., Vol. 283, Issue 22, 15309-15318, May 30, 2008
This Article
Free via Author's Choice: AC
Right arrow AC Full Text
Right arrow Full Text (PDF)
Right arrowAC All Versions of this Article:
283/22/15309    most recent
M708289200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kao, C.-Y.
Right arrow Articles by Wu, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kao, C.-Y.
Right arrow Articles by Wu, R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Requirements for Two Proximal NF-{kappa}B Binding Sites and I{kappa}B-{zeta} in IL-17A-induced Human β-Defensin 2 Expression by Conducting Airway Epithelium*

Cheng-Yuan Kao, Christy Kim, Fei Huang, and Reen Wu1

From the Center for Comparative Respiratory Biology and Medicine, University of California, Davis, California 95616

Among a panel of 21 cytokines (IL-1{alpha}, -1β, -2–13, and -15–18; interferon-{gamma}; granulocyte-macrophage colony-stimulating factor; and tumor necrosis factor {alpha}), we have recently observed that IL-17A is the most potent inducer for human β-defensin 2 (hBD-2) in conducting airway epithelial cells (Kao, C. Y., Chen, Y., Thai, P., Wachi, S., Huang, F., Kim, C., Harper, R. W., and Wu, R. (2004) J. Immunol. 173, 3482–3491). The molecular basis of this regulation is not known. In this study, we demonstrated a coordinated degradation of inhibitory {kappa}B(I{kappa}B)-{alpha} followed by a nuclear translocation of p50 and p65 NF-{kappa}B subunits and their binding to NF-{kappa}B sites of hBD-2 promoter region. With site-directed mutagenesis, we demonstrated the requirement of two proximal NF-{kappa}B binding sites (p{kappa}B1, -205 to -186; p{kappa}B2, -596 to -572) but not the distal site (d{kappa}B, -2193 to -2182) in supporting IL-17A-induced hBD-2 promoter activity. These results are consistent with the data of the chromatin immunoprecipitation assay, which showed enhanced p50 binding to these p{kappa}B sites but not the d{kappa}B site in cells after IL-17A treatment. We also found that the NF-{kappa}B binding cofactor, I{kappa}B-{zeta}, was up-regulated by IL-17A, and the knockdown of I{kappa}B-{zeta} significantly diminished the IL-17A-induced hBD-2 expression. This is the first demonstration of the involvement of two proximal NF-{kappa}B sites and I{kappa}B-{zeta} in the regulation of hBD-2 by IL-17A, two important genes responsible for host defense.


Received for publication, October 5, 2007 , and in revised form, March 11, 2008.

* This work was supported, in whole or in part, by National Institutes of Health Grants HL35635, HL077902, HL077315, and ES00628. This work was also supported by California Tobacco-Related Disease Research Program Grant 16RT-0127. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Formula Author's Choice—Final version full access.

Author's Choice

Creative Commons Attribution Non-Commercial License applies to Author Choice Articles

1 To whom correspondence should be addressed: Center for Comparative Respiratory Biology and Medicine Genome and Biomedical Science Facility, Suite 6523, University of California, 451 Health Science Dr., Davis, CA 95616. Tel.: 530-752-2648; Fax: 530-752-8632; E-mail: rwu{at}ucdavis.edu.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement